4536 — Santen Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Santen Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	241,555	249,605	266,257	279,037	301,965
Cost of Revenue
Gross Profit	146,724	151,384	156,586	166,087	178,709
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	209,169	237,410	228,890	282,425	264,302
Operating Profit	32,386	12,195	37,367	-3,388	37,663
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	32,091	11,688	35,616	-5,799	29,874
Provision for Income Taxes
Net Income After Taxes	21,714	9,126	27,189	-14,983	26,703
Minority Interest
Net Income Before Extraordinary Items
Net Income	23,618	9,311	27,218	-14,948	26,643
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	23,620	9,311	27,218	-14,955	26,642
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	71.6	72.7	65.3	26.3	109
Dividends per Share